{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:57:01Z","timestamp":1779249421721,"version":"3.51.4"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.yrtph.2020.104667","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T12:38:55Z","timestamp":1588682335000},"page":"104667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Application of structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic model development and evaluation"],"prefix":"10.1016","volume":"114","author":[{"given":"Corie A.","family":"Ellison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengde","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.1985.tb02799.x","article-title":"Caffeine disposition in obesity","volume":"20","author":"Abernethy","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.yrtph.2020.104667_bib2","first-page":"883","article-title":"Comparative pharmacokinetics of oral and intravenous ifosfamide\/mesna\/methylene blue therapy","volume":"26","author":"Aeschlimann","year":"1998","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01067905","article-title":"Pharmacokinetics of diphenhydramine in man","volume":"3","author":"Albert","year":"1975","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"274","key":"10.1016\/j.yrtph.2020.104667_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0447.1978.tb02387.x","article-title":"The pharmacokinetic profile of oxazepam","author":"Alv\u00e1n","year":"1978","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"5","key":"10.1016\/j.yrtph.2020.104667_bib5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2125.1981.tb01157.x","article-title":"Trazodone--a new assay procedure and some pharmacokinetic parameters","volume":"11","author":"Ankier","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.yrtph.2020.104667_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2125.1981.tb01282.x","article-title":"Theophylline pharmacokinetics in advanced age","volume":"12","author":"Antal","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.1981.tb00533.x","article-title":"Comparative pharmacokinetics of theophylline and aminophylline in man","volume":"11","author":"Aslaksen","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.104.002436","article-title":"The binding of drugs to hepatocytes and its relationship to physicochemical properties","volume":"33","author":"Austin","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF00314996","article-title":"Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers","volume":"41","author":"Bano","year":"1991","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2020.104667_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tiv.2017.11.016","article-title":"In vitro to in vivo extrapolation for high throughput prioritization and decision making","volume":"47","author":"Bell","year":"2018","journal-title":"Toxicol. Vitro"},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.1982.176","article-title":"Diphenhydramine: kinetics and psychomotor effects in elderly women","volume":"32","author":"Berlinger","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yrtph.2013.11.008","article-title":"PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop","volume":"68","author":"Bessems","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2020.104667_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01061844","article-title":"Comparative pharmacokinetics of caffeine in young and elderly men","volume":"11","author":"Blanchard","year":"1983","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"12","key":"10.1016\/j.yrtph.2020.104667_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/jps.2600711229","article-title":"Protein binding of caffeine in young and elderly males","volume":"71","author":"Blanchard","year":"1982","journal-title":"J. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.yrtph.2020.104667_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/j.1552-4604.1986.tb02946.x","article-title":"Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration","volume":"26","author":"Blyden","year":"1986","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/clpt.1982.132","article-title":"Caffeine disposition after oral doses","volume":"32","author":"Bonati","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.yrtph.2020.104667_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11095-019-2645-0","article-title":"Interlaboratory variability in human hepatocyte intrinsic clearance values and trends with physicochemical properties","volume":"36","author":"Bowman","year":"2019","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"9","key":"10.1016\/j.yrtph.2020.104667_bib18","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","article-title":"Pharmacokinetics of linezolid in subjects with renal dysfunction","volume":"47","author":"Brier","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.yrtph.2020.104667_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/cpt1978234375","article-title":"Correlation between plasma diphenhydramine level and sedative and antihistamine effects","volume":"23","author":"Carruthers","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00273399","article-title":"Bioavailability of ifosfamide in patients with bronchial carcinoma","volume":"18","author":"Cerny","year":"1986","journal-title":"Canc. Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yrtph.2007.10.012","article-title":"Development and specification of physiologically based pharmacokinetic models for use in risk assessment","volume":"50","author":"Clewell","year":"2008","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2020.104667_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF03189792","article-title":"Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal","volume":"22","author":"Cohen","year":"1997","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00315209","article-title":"Effects of moderate exercise on the pharmacokinetics of caffeine","volume":"40","author":"Collomp","year":"1991","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.clpt.6100211","article-title":"Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine","volume":"82","author":"Cysneiros","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yrtph.2020.104667_bib89","series-title":"Chemistry Collection: Basic Chemistry User Guide","year":"2011"},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00204-014-1421-5","article-title":"SEURAT: safety evaluation ultimately replacing animal testing--recommendations for futureresearch in the field of predictive toxicology","volume":"89","author":"Daston","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.yrtph.2020.104667_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tiv.2018.02.017","article-title":"A strategy for systemic toxicity assessment based on non-animal approaches: the CosmeticsEurope Long Range Science Strategy programme","volume":"50","author":"Desprez","year":"2018","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.yrtph.2020.104667_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yrtph.2018.09.008","article-title":"Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation","volume":"99","author":"Ellison","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib28","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/clpt.2008.293","article-title":"Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem","volume":"85","author":"Farkas","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2125.1984.tb02485.x","article-title":"Comparative bioavailability of trazodone formulations using stable isotope methodology","volume":"18","author":"Gammans","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.yrtph.2020.104667_bib30","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/0091270003257455","article-title":"The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E","volume":"43","author":"Gordi","year":"2003","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2020.104667_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/j.1552-4604.1984.tb01829.x","article-title":"Interaction of cimetidine with oxazepam, lorazepam, and flurazepam","volume":"24","author":"Greenblatt","year":"1984","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2020.104667_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/clpt.1987.132","article-title":"Trazodone kinetics: effect of age, gender, and obesity","volume":"42","author":"Greenblatt","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0091270009336444","article-title":"Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone","volume":"50","author":"Gr\u00f6nlund","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00228-008-0568-5","article-title":"Voriconazole drastically increases exposure to oral oxycodone","volume":"65","author":"Hagelberg","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.yrtph.2020.104667_bib35","first-page":"525","article-title":"Absolute bioavailability of oral theophylline","volume":"34","author":"Hendeles","year":"1977","journal-title":"Am. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00981135","article-title":"Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration","volume":"31","author":"Heykants","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2020.104667_bib37","year":"2010"},{"issue":"7","key":"10.1016\/j.yrtph.2020.104667_bib38","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1021\/acs.chemrestox.9b00030","article-title":"Binding modes and metabolism of caffeine","volume":"vol. 32","author":"Jandova","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"8","key":"10.1016\/j.yrtph.2020.104667_bib39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/j.1552-4604.1997.tb04356.x","article-title":"Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans","volume":"37","author":"Kaplan","year":"1997","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.yrtph.2020.104667_bib40","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1007\/BF01613221","article-title":"Metabolism and pharmacokinetics of oral and intravenous ifosfamide","volume":"117","author":"Kurowski","year":"1991","journal-title":"J. Canc. Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.yrtph.2020.104667_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0006-3223(96)00521-5","article-title":"Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chlorophenylpiperazine and trazodone in human volunteers","volume":"41","author":"Lawlor","year":"1997","journal-title":"Biol. Psychiatr."},{"issue":"7","key":"10.1016\/j.yrtph.2020.104667_bib87","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.2042-7158.1997.tb06092.x","article-title":"A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in-vivo permeability estimation","volume":"49","author":"Lennern\u00e4s","year":"1997","journal-title":"J Pharm Pharmacol"},{"issue":"11","key":"10.1016\/j.yrtph.2020.104667_bib43","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/jps.2600681114","article-title":"Pharmacokinetics and relative bioavailability of oral theophylline capsules","volume":"68","author":"Lesko","year":"1979","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.yrtph.2020.104667_bib44","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.yrtph.2017.12.026","article-title":"Structure activity relationship (SAR) toxicological assessments: the role of expert judgment","volume":"92","author":"Lester","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib45","first-page":"753","article-title":"Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma","volume":"49","author":"Lind","year":"1989","journal-title":"Canc. Res."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2125.1996.00481.x","article-title":"Characterization and validation of a pharmacokinetic model for controlled-release oxycodone","volume":"42","author":"Mandema","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2020.104667_bib47","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejps.2016.10.036","article-title":"Imi - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 2: an introduction to the simulation exercise and overview of results","volume":"96","author":"Margolskee","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"2","key":"10.1016\/j.yrtph.2020.104667_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.vascn.2005.08.005","article-title":"Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance","volume":"53","author":"Nagilla","year":"2006","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"8","key":"10.1016\/j.yrtph.2020.104667_bib49","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejpain.2009.12.007","article-title":"St John's wort greatly reduces the concentrations of oral oxycodone","volume":"14","author":"Nieminen","year":"2010","journal-title":"Eur. J. Pain"},{"issue":"2","key":"10.1016\/j.yrtph.2020.104667_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1600-0773.1992.tb00535.x","article-title":"Single dose pharmacokinetics of trazodone in healthy subjects","volume":"71","author":"Nilsen","year":"1992","journal-title":"Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.yrtph.2020.104667_bib51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4062\/biomolther.2014.134","article-title":"Effects of baicalin on oral pharmacokinetics of caffeine in rats","volume":"23","author":"Noh","year":"2015","journal-title":"Biomol Ther (Seoul)."},{"issue":"7","key":"10.1016\/j.yrtph.2020.104667_bib52","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1124\/dmd.108.020479","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drugcompounds","volume":"36","author":"Obach","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"16","key":"10.1016\/j.yrtph.2020.104667_bib53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF01721774","article-title":"Disposition of oxazepam in patients on maintenance hemodialysis","volume":"62","author":"Ochs","year":"1984","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.yrtph.2020.104667_bib54","series-title":"OECD Guidelines for the Testing of Chemicals, Section 3, Environmental Fate and Behaviour. Test No. 319A: Determination of in Vitro Intrinsic Clearance Using Cryopreserved Rainbow Trout Hepatocytes (RT-HEP)","year":"2018"},{"key":"10.1016\/j.yrtph.2020.104667_bib55","series-title":"OECD Guidelines for the Testing of Chemicals, Section 3, Environmental Fate and Behaviour. Test No. 319B: Determination of in Vitro Intrinsic Clearance Using Rainbow Trout Liver S9 Sub-cellular Fraction (RT-S9)","year":"2018"},{"issue":"9","key":"10.1016\/j.yrtph.2020.104667_bib56","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.2042-7158.2011.01326.x","article-title":"Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics","volume":"63","author":"Perera","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","article-title":"The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects","volume":"33","author":"P\u00f6yhi\u00e4","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00544018","article-title":"Pharmacokinetics of ketanserin in man","volume":"25","author":"Reimann","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib59","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2125.1982.tb02035.x","article-title":"Pharmacokinetics of theophylline: a dose-range study","volume":"14","author":"Rovei","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2020.104667_bib60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-009-0775-8","article-title":"Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone","volume":"66","author":"Saari","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.yrtph.2020.104667_bib61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/j.1552-4604.1998.tb04466.x","article-title":"Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers","volume":"38","author":"Scavone","year":"1998","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib62","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.yrtph.2015.05.016","article-title":"A strategy for structuring and reporting a read-across prediction of toxicity","volume":"72","author":"Schultz","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2020.104667_bib63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jps.2600680238","article-title":"Theophylline protein binding in humans","volume":"68","author":"Simons","year":"1979","journal-title":"J. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.yrtph.2020.104667_bib64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/j.1552-4604.1990.tb01871.x","article-title":"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children","volume":"30","author":"Simons","year":"1990","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.yrtph.2020.104667_bib65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00228-001-0380-y","article-title":"Age and sex effects on the pharmacokinetics of linezolid","volume":"57","author":"Sisson","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2020.104667_bib66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00561369","article-title":"Bioavailability and pharmacokinetics of oxazepam","volume":"35","author":"Sonne","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.yrtph.2020.104667_bib67","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/jac\/dkg180","article-title":"Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers","volume":"51","author":"Stalker","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.yrtph.2020.104667_bib68","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.fct.2007.05.023","article-title":"Herb-drug interactions: effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats","volume":"45","author":"Tang","year":"2007","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/bdd.234","article-title":"Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride","volume":"21","author":"Toothaker","year":"2000","journal-title":"Biopharm Drug Dispos."},{"issue":"6","key":"10.1016\/j.yrtph.2020.104667_bib70","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00005344-198311000-00018","article-title":"Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man","volume":"5","author":"Trenk","year":"1983","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.yrtph.2020.104667_bib71","volume":"Apr","year":"2015"},{"issue":"12","key":"10.1016\/j.yrtph.2020.104667_bib72","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","article-title":"Predicting clearance mechanism in drug discovery: extended clearance classification system(ECCS)","volume":"32","author":"Varma","year":"2015","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"12","key":"10.1016\/j.yrtph.2020.104667_bib73","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.47.12.3789-3794.2003","article-title":"Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose","volume":"47","author":"Wagenlehner","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/toxsci\/kfv118","article-title":"Toxicokinetic triage for environmental chemicals","volume":"147","author":"Wambaugh","year":"2015","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0091-3057(97)00595-9","article-title":"Caffeine has similar pharmacokinetics and behavioral effects via the i.p. and p.o. routes of administration","volume":"60","author":"Wang","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.yrtph.2020.104667_bib76","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/bdd.255","article-title":"Linezolid absolute bioavailability and the effect of food on oral bioavailability","volume":"22","author":"Welshman","year":"2001","journal-title":"Biopharm Drug Dispos."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib77","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/toxsci\/kfr254","article-title":"Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment","volume":"125","author":"Wetmore","year":"2012","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/toxsci\/kfv171","article-title":"Incorporating high-throughput exposure predictions with dosimetry-adjusted in vitro bioactivity to inform chemical toxicity testing","volume":"148","author":"Wetmore","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2020.104667_bib79","article-title":"Administrator memo prioritizing efforts to reduce animal testing","volume":"10","author":"Wheeler","year":"2019","journal-title":"September"},{"key":"10.1016\/j.yrtph.2020.104667_bib80","series-title":"Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment","author":"World Health Organization","year":"2010"},{"issue":"11","key":"10.1016\/j.yrtph.2020.104667_bib81","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.117.077040","article-title":"Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocytes\/microsomes and implications for experimental methodology","volume":"45","author":"Wood","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yrtph.2009.09.006","article-title":"A framework for using structural, reactivity, metabolic and physicochemical similarity to evaluatethe suitability of analogs for SAR-based toxicological assessments","volume":"56","author":"Wu","year":"2010","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"5","key":"10.1016\/j.yrtph.2020.104667_bib83","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/dmd.107.018499","article-title":"Time-dependent effects of Klebsiella pneumoniae endotoxin (KPLPS) on the pharmacokinetics of theophylline in rats: return of the parameters in 96-hour KPLPS rats to the control levels","volume":"36","author":"Yang","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.yrtph.2020.104667_bib84","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1023\/A:1011930411574","article-title":"Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds","volume":"15","author":"Yazdanian","year":"1998","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"1","key":"10.1016\/j.yrtph.2020.104667_bib85","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/toxsci\/kfp198","article-title":"Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model","volume":"112","author":"Yoon","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2020.104667_bib86","series-title":"Treatment of Hypertension with Urapidil : Preclinical and Clinical Update","first-page":"29","article-title":"Pharmacokinetics of urapidil in normal subjects","author":"Zech","year":"1986"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230020300933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230020300933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:30:30Z","timestamp":1759494630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230020300933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":88,"alternative-id":["S0273230020300933"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2020.104667","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic model development and evaluation","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2020.104667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104667"}}